Technology
Galleon has a unique and proven purpose-built, drug-discovery platform for the design, discovery and development of breathing-control medicines that serve a wide range of therapeutic needs.
Our Approach:
Recent scientific breakthroughs are rapidly increasing our understanding of how the human body controls breathing.
The Galleon technology platform employs multi-dimensional analysis to simultaneously assess breathing control, cardiovascular, and neuromuscular variables.
Utilizing sophisticated in vivo proprietary modeling methods we evaluate both the normal and disordered neurobiological basis of breathing control.
Drawing on medical expertise from multiple disciplines we are evaluating a wide range of mechanisms of action depending on the therapeutic target and desired clinical benefit.
Galleon has developed a sophisticated multi-dimensional electrophysiology system that allows for simultaneous characterization of respiratory drive, respiratory mechanics, cardiovascular and neuromuscular endpoints.
Development candidates for sleep apnea are targeting respiratory drive, Loop Gain, upper airway muscle strength and neural tone.
